Apricus Biosciences Inc (APRI.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2013||Chairman of the Board|
|52||2016||Chief Executive Officer, Principal Accounting Officer, Secretary, Director|
|47||2014||Senior Vice President, Chief Development Officer|
- Shares of Apricus tank after FDA declines to OK erectile dysfunction cream
- BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros
- U.S. FDA declines to approve Apricus' erectile dysfunction cream
- BRIEF-Apricus Biosciences files for mixed shelf of up to $100 million
- BRIEF-Apricus Biosciences files for resale of up to 3.3 mln of common stock by selling stockholders